|
gptkbp:instanceOf
|
gptkb:antiretroviral_therapy
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:dolutegravir
gptkb:abacavir
gptkb:lamivudine
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
August 2014
|
|
gptkbp:ATCCode
|
gptkb:J05AR13
|
|
gptkbp:brand
|
abacavir/dolutegravir/lamivudine
|
|
gptkbp:contraindication
|
severe liver impairment
HLA-B*5701 positive
|
|
gptkbp:countryApproved
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:drugInteraction
|
gptkb:phenytoin
gptkb:rifampin
gptkb:carbamazepine
gptkb:St._John's_wort
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketingAuthorizationHolder
|
gptkb:ViiV_Healthcare
|
|
gptkbp:mechanismOfAction
|
gptkb:protease_inhibitor
|
|
gptkbp:notRecommendedFor
|
children under 12 years
|
|
gptkbp:onceDaily
|
true
|
|
gptkbp:pregnancyCategory
|
N
|
|
gptkbp:prescribes
|
adolescents with HIV
adults with HIV
|
|
gptkbp:prescriptionRequired
|
true
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
fatigue
headache
insomnia
hypersensitivity reaction
|
|
gptkbp:storage
|
below 30°C
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:dolutegravir
gptkb:ViiV_Healthcare
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Triumeq
|